Job Trends
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Career Advice
If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.
THE LATEST
Adding Yervoy to the therapy did not improve overall survival (OS) or progression-free survival (PFS) but did add toxicity to Keytruda monotherapy.
Gilead Sciences has inked a collaboration, option and license deal with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.
While companies around the globe reduce staff amidst economic upheaval, there’s at least one industry on the rise - life sciences. Here’s who’s breaking ground on expansion projects.
It was a busy week for clinical trial news. Read on for more information.
Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca for the last few months has been on their COVID-19 vaccine efforts.
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate its investigational monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate COVID-19.
While many industries are struggling, biopharma is booming. Here’s an overview of last month’s company expansion announcements, who’s growing their footprint and adding more jobs.
Novartis shares were down by 4.4% as the market opened, following the announcement on its earnings call of a disappointing $2.1 billion in net profits and $0.92 earnings per share for 4Q20, below most investor estimates.
Regeneron announced positive initial data from its ongoing Phase III trial of its antibody cocktail, REGEN-COV, as a passive vaccine to prevent COVID-19 in people at high risk of infection from household exposure.
Roche announced topline data from two identical Phase III trials, TENAYA and LUCERNE, of faricimab in neovascular or “wet” age-related macular degeneration (nAMD).